The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. 2008

D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. D.Burger@akf.umcn.nl

Atazanavir (ATV) is known to inhibit UGT1A1-mediated glucuronidation. Here we report the effect of ATV and ATV/ritonavir (RTV) on another UGT1A isoenzyme, UGT1A4. Twenty-one healthy volunteers received a single dose of 100 mg of oral lamotrigine on days 1, 13, and 27; on each occasion blood was sampled before the dose was administered and through 120 h after ingestion of the drug. On days 8-17 the subjects received oral ATV 400 mg q.d. On days 18-30 the subjects received oral ATV 300 mg plus oral RTV 100 mg q.d. Seventeen subjects were evaluable for pharmacokinetic analysis. Geometric mean ratios (+90% confidence intervals (CIs)) of lamotrigine area under the plasma concentration-time curve (AUC)(0-inf) and peak plasma concentration (C(max)) for ATV + lamotrigine and for lamotrigine alone were 0.88 (0.86-0.91) and 0.99 (0.95-1.02), respectively; the corresponding ratios for ATV/RTV and for lamotrigine were 0.68 (0.65-0.70) and 0.94 (0.90-0.97), respectively. The mean ratio of lamotrigine-2N-glucuronide to lamotrigine AUC(0-inf) increased from 0.45 for lamotrigine to 0.71 for ATV/RTV + lamotrigine. ATV alone does not significantly influence glucuronidation of lamotrigine. In contrast, ATV/RTV results in moderately decreased exposure to lamotrigine.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
November 2006, Hepatology (Baltimore, Md.),
D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
November 2011, Archives of toxicology,
D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
July 2011, British journal of clinical pharmacology,
D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
May 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
December 2007, Drug and alcohol dependence,
D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
March 2010, International journal of clinical pharmacology and therapeutics,
D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
May 2010, Antiviral research,
D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
October 1989, Biochemistry,
D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
July 2003, Biochemical pharmacology,
D M Burger, and A Huisman, and N Van Ewijk, and H Neisingh, and P Van Uden, and G A Rongen, and P Koopmans, and R J Bertz
June 2008, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!